Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development SCOTCH PLAINS, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage ...
The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors ...
FSCO delivers strong total returns with a 33.1% one-year total return and a 10.8% yield. Read what supports my continued buy rating for FSCO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback